A new Spherix Global Insights survey shows providers want administrative support for prior authorization while patients prioritize access and affordability
News|Articles|July 1, 2008
Integrating Recent Growth Factor Evidence, Practice Guidelines, and FDA Recommendations: Validating the Pharmacist?s Role in Management
Epoetin alfa in 1993 and darbepoetin alfa in 2002 were approved for the management of chemotherapy-induced anemia (CIA).
Advertisement
Advertisement
Related to this article
Pharmacy benefit managers are moving beyond formulary access to provide support programs for women's health. Here's how three PBMs — Judi Health, LucyRx and RxPreferred — are putting that strategy into practice.
Women face more gaps in healthcare than men, from missed screenings, undertreatment and biased coverage. PBMs are launching programs to address some of the gaps.
Navitus launched three modular options that let plan sponsors manage diabetes, weight, and lifestyle therapy access, cost, and outcomes with guaranteed ROI.
StarkRx has launched as a modular, cost-plus pharmacy benefit management company for self-funded employers using Judi Health’s PBM, Judi Rx, to administer claims.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Alexis Sova, Pharm.D., MBA, on where GLP-1 coverage goes next | PBMI 2026
2
Systemic inflammation present even in mild hidradenitis suppurativa
3
Alexis Sova, Pharm.D., MBA, on GLP-1 access when coverage ends | PBMI 2026
4
Large study finds GLP-1 drugs may lower fracture risk in Type 2 diabetes
5